泽璟制药(688266.SH)：注射用ZG005、注射用ZGGS18与盐酸吉卡昔替尼片联合用于晚期实体瘤的临床试验获得批准

Core Viewpoint - Zai Jian Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of its innovative cancer immunotherapy products, ZG005 and ZGGS18, in combination with JAK and ACVR1 dual inhibitor, JAK inhibitor [1] Group 1 - ZG005 is a recombinant humanized anti-PD-1/TIGIT bispecific antibody classified as a Class 1 innovative tumor immunotherapy biological product, expected to treat various solid tumors [1] - ZG005 is one of the first drugs globally to enter clinical research targeting the same mechanism, with no similar mechanism drugs approved for market worldwide [1] - ZGGS18 is a recombinant humanized bispecific antibody fusion protein targeting VEGF/TGF-β, classified as a Class 1 therapeutic biological product, anticipated to be an innovative treatment for solid tumors [1] Group 2 - JAK inhibitor, also known as JAK and ACVR1 dual inhibitor, is a new Class 1 drug independently developed by the company, which holds the intellectual property rights for this product [1]